These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 9769391)

  • 1. Treatments for newly diagnosed multiple myeloma: analysis of survival data and cost-effectiveness evaluation.
    Trippoli S; Messori A; Becagli P; Alterini R; Tendi E
    Oncol Rep; 1998; 5(6):1475-82. PubMed ID: 9769391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-utility analysis of melphalan plus prednisone with or without interferon-alpha 2b in newly diagnosed multiple myeloma. Results from a randomised controlled trial.
    Nord E; Wisløff F; Hjorth M; Westin J
    Pharmacoeconomics; 1997 Jul; 12(1):89-103. PubMed ID: 10169390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of high-dose melphalan with autologous blood stem cell support vs. melphalan plus prednisone in patients younger than 60 years with multiple myeloma.
    Gulbrandsen N; Wisløff F; Nord E; Lenhoff S; Hjorth M; Westin J;
    Eur J Haematol; 2001 May; 66(5):328-36. PubMed ID: 11422413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatments for newly diagnosed advanced ovarian cancer: analysis of survival data and cost-effectiveness evaluation.
    Messori A; Trippoli S; Becagli P; Tendi E
    Anticancer Drugs; 1998 Jul; 9(6):491-502. PubMed ID: 9877236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
    van Agthoven M; Segeren CM; Buijt I; Uyl-de Groot CA; van der Holt B; Lokhorst HM; Sonneveld P
    Eur J Cancer; 2004 May; 40(8):1159-69. PubMed ID: 15110879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.
    Powles R; Raje N; Horton C; Mehta J; Singhal S; Hickish T; Viner C; Milan S; Treleaven J; Cunningham D
    Leuk Lymphoma; 1996 May; 21(5-6):421-7. PubMed ID: 9172806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
    Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J
    J Clin Oncol; 1994 Apr; 12(4):759-63. PubMed ID: 8151319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results.
    Hillner BE; Smith TJ; Desch CE
    JAMA; 1992 Apr; 267(15):2055-61. PubMed ID: 1552641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance treatment with recombinant alpha interferon after autologous bone marrow transplantation for aggressive myeloma in first remission after conventional induction chemotherapy.
    Attal M; Huguet F; Schlaifer D; Payen C; Lassoued S; Laroche M; Rossi JF; Fournie B; Mazieres B; Pris J
    Bone Marrow Transplant; 1991 Aug; 8(2):125-8. PubMed ID: 1933053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined submyeloablative and myeloablative dose intense melphalan results in satisfactory responses with acceptable toxicity in patients with multiple myeloma.
    Novitzky N; Thomson J; Thomas V; du Toit C; Mohamed Z; McDonald A
    Biol Blood Marrow Transplant; 2010 Oct; 16(10):1402-10. PubMed ID: 20385248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of a transplantation strategy compared to melphalan and prednisone in younger patients with multiple myeloma.
    Kouroukis CT; O'Brien BJ; Benger A; Marcellus D; Foley R; Garner J; Ingram C; Haines P; Henderson-O'Connor N; Meyer R
    Leuk Lymphoma; 2003 Jan; 44(1):29-37. PubMed ID: 12691140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long term evaluation of the impact of autologous peripheral blood stem cell transplantation in multiple myeloma: a cost-effectiveness analysis.
    Corso A; Mangiacavalli S; Cocito F; Pascutto C; Ferretti VV; Pompa A; Ciampichini R; Pochintesta L; Mantovani LG
    PLoS One; 2013; 8(9):e75047. PubMed ID: 24098678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.
    Raje N; Powles R; Horton C; Millar B; Shepherd V; Middleton G; Kulkarni S; Eisen T; Mehta J; Singhal S; Treleaven J
    Br J Cancer; 1997; 75(11):1684-9. PubMed ID: 9184187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of multiple myeloma--melphalan monotherapy after bone marrow transplantation].
    Hájek R; Adam Z; Krejcí M; Vásová I; Král Z; Vorlícek J
    Vnitr Lek; 1996 Apr; 42(4):278-84. PubMed ID: 8693716
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of multiple myeloma.
    San Miguel JF; Bladé Creixenti J; García-Sanz R
    Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma.
    Messori A; Bonistalli L; Costantini M; Alterini R
    Bone Marrow Transplant; 1997 Feb; 19(3):275-81. PubMed ID: 9028558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative survival, quality of life and cost-effectiveness of intensive therapy with autologous blood cell transplantation or conventional chemotherapy in multiple myeloma.
    Henon P; Donatini B; Eisenmann JC; Becker M; Beck-Wirth G
    Bone Marrow Transplant; 1995 Jul; 16(1):19-25. PubMed ID: 7581122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose chemotherapy in multiple myeloma.
    Goldschmidt H; Hegenbart U; Wallmeier M; Moos M; Haas R
    Leukemia; 1997 Dec; 11 Suppl 5():S27-31. PubMed ID: 9436935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.
    Powles R; Raje N; Cunningham D; Malpas J; Milan S; Horton C; Mehta J; Singhal S; Viner C; Treleaven J
    Stem Cells; 1995 Aug; 13 Suppl 2():114-7. PubMed ID: 8520498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.